Kymera Therapeutics, Inc. (KYMR)Healthcare | Biotechnology | Watertown, United States | NasdaqGM
108.14 USD
+1.31
(1.226%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 108.14 |
Hot Take ↕ | Oct. 10, 2026, 11:12 a.m. EDT
Kymera Therapeutics presents a high-risk, high-reward profile anchored by a fortress balance sheet. Despite the absence of profitability and negative earnings estimates, the company holds substantial net cash, insulating it from immediate capital raising pressures while it advances its pipeline. The five-year price history reflects a resilient upward trend, validating the market's patience with its growth strategy. However, the stock trades below its 50-day moving average, indicating short-term weakness, and statistical models suggest a slight downside bias for the coming month. Options activity reveals a bullish undercurrent, with significant call positioning at higher strikes, though elevated implied volatility signals uncertainty. Investors should view this as a speculative growth play where the financial safety net outweighs the earnings risk, provided they can tolerate the inherent volatility of the biotech sector. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.058858 |
| AutoETS | 0.059554 |
| AutoARIMA | 0.059704 |
| AutoTheta | 0.103601 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 1.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.487 |
| Excess Kurtosis | -0.57 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.205 |
| Revenue per Share | 1.126 |
| Market Cap | 8,991,907,840 |
| Forward P/E | -21.21 |
| Beta | 1.98 |
| Profit Margins | -285.33% |
| Website | https://www.kymeratx.com |
As of Oct. 10, 2026, 11:12 a.m. EDT: Speculators are positioning for continued upside with significant call volume concentrated at higher strikes (140 and 145), indicating bullish bets on further appreciation. However, deep out-of-the-money put options show substantial open interest, suggesting hedging or contrarian bets against a sharp decline. Implied volatility remains elevated, reflecting market uncertainty despite the bullish call flow.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.78555906 |
| Address1 | 500 North Beacon Street |
| Address2 | 4th Floor |
| All Time High | 130.05 |
| All Time Low | 9.6 |
| Ask | 133.99 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 947,470 |
| Average Daily Volume3 Month | 726,563 |
| Average Volume | 726,563 |
| Average Volume10Days | 947,470 |
| Beta | 1.984 |
| Bid | 75.27 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 18.23 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 108.14 |
| Current Ratio | 10.337 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 110.68 |
| Day Low | 104.625 |
| Debt To Equity | 5.205 |
| Display Name | Kymera Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,933,000 |
| Earnings Call Timestamp Start | 1,785,933,000 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | -339,891,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -24.653 |
| Enterprise To Revenue | 79.805 |
| Enterprise Value | 8,379,480,576 |
| Eps Current Year | -3.85054 |
| Eps Forward | -5.09736 |
| Eps Trailing Twelve Months | -3.29 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 114.9614 |
| Fifty Day Average Change | -6.8214035 |
| Fifty Day Average Change Percent | -0.05933647 |
| Fifty Two Week Change Percent | 78.55591 |
| Fifty Two Week High | 130.05 |
| Fifty Two Week High Change | -21.910004 |
| Fifty Two Week High Change Percent | -0.16847369 |
| Fifty Two Week Low | 55.26 |
| Fifty Two Week Low Change | 52.88 |
| Fifty Two Week Low Change Percent | 0.95693094 |
| Fifty Two Week Range | 55.26 - 130.05 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,598,016,600,000 |
| Float Shares | 66,039,884 |
| Forward Eps | -5.09736 |
| Forward P E | -21.214903 |
| Free Cashflow | -144,066,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 273 |
| Fullday Change | 1.3099976 |
| Fullday Change Percent | 1.226245 |
| Fullday Price | 108.14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -2.57685 |
| Gross Profits | -270,568,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02121 |
| Held Percent Institutions | 1.19403 |
| Implied Shares Outstanding | 83,150,618 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-08-21 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts. |
| Long Name | Kymera Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 8,991,907,840 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_542085131 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -299,600,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,596,412,823 |
| Number Of Analyst Opinions | 23 |
| Open | 106.52 |
| Operating Cashflow | -236,762,000 |
| Operating Margins | -1.16318 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 857 285 5300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 108.14 |
| Post Market Time | 1,792,096,860 |
| Previous Close | 106.83 |
| Price Eps Current Year | -28.084373 |
| Price Hint | 2 |
| Price To Book | 5.93198 |
| Price To Sales Trailing12 Months | 85.637215 |
| Profit Margins | -2.8533401 |
| Quick Ratio | 9.968 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.375 |
| Region | US |
| Regular Market Change | 1.31 |
| Regular Market Change Percent | 1.22624 |
| Regular Market Day High | 110.68 |
| Regular Market Day Low | 104.625 |
| Regular Market Day Range | 104.625 - 110.68 |
| Regular Market Open | 106.52 |
| Regular Market Previous Close | 106.83 |
| Regular Market Price | 108.14 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 820,991 |
| Return On Assets | -0.15592 |
| Return On Equity | -0.24154 |
| Revenue Growth | 4.664 |
| Revenue Per Share | 1.126 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 83,150,618 |
| Shares Percent Shares Out | 0.1192 |
| Shares Short | 9,910,014 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,371,554 |
| Short Name | Kymera Therapeutics, Inc. |
| Short Percent Of Float | 0.1533 |
| Short Ratio | 13.18 |
| Source Interval | 15 |
| State | MA |
| Symbol | KYMR |
| Target High Price | 180.0 |
| Target Low Price | 111.0 |
| Target Mean Price | 139.34782 |
| Target Median Price | 139.0 |
| Total Cash | 690,985,024 |
| Total Cash Per Share | 8.31 |
| Total Debt | 78,558,000 |
| Total Revenue | 105,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 94.0736 |
| Two Hundred Day Average Change | 14.066399 |
| Two Hundred Day Average Change Percent | 0.14952546 |
| Type Disp | Equity |
| Volume | 820,991 |
| Website | https://www.kymeratx.com |
| Zip | 2,472 |